Innovation towards improved infertility treatments

We develop new drugs to activate eggs in infertile women

Opportunity

- The global fertilization market is projected to reach $27 Billion by 2022 (Grand View Research, Inc)

Market drivers

- Aging population
- Obesity
- Increased awareness
- Reimbursement and insurances
- Strong reproductive instinct

Assets

- Growing marked
- Strong scientific team (Scientific researchers >10 years of follicle expertise, fertility consultants, strong records in animal modeling) and management (experienced Business developers)
- IP rights
- Soft funding for further development

Technology Description

Our invention is based in specific data sets that analysed global expression of genes during the earliest stages in egg maturation. We identified novel potential targets and are currently developing new drugs to enhance activation of dormant eggs in the ovary. The targets identified are highly present in the early egg cells and through proof of concept in vitro and ex vivo studies, we showed that pharmacological treatment could promote activation of the earliest egg cells.

We are working towards maturing the technology in a spin-out company.

Intellectual Property Rights


Current State

In vitro and ex vivo proof-of-concept has been established. Currently, lead compounds are being developed for the validated targets. The project is, at this stage, funded by soft funding.

In vivo confirmation, CMC and toxicity studies initiated. Phase I/IIa clinical trial is expected in 2021/2022.

Team

- Associate Professor Karin Lykke-Hartmann
  Scientific lead and project management

- PhD Per Horn
  Business and project management

- Technician Anders Heuck
  Single cell techniques

- Postdoc Mahbboobeh Amoushahi,
  Cellular cultures and translational models

- Professor Erik Ernst
  Fertility treatment

Call to action

We are looking to develop collaborations and partnerships for registration studies with companies that has experience in fertility treatment.

Contact information

Morten Holmager
Business Development Manager
Mobile: +45 9350 8718
E-mail: holmager@au.dk